These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34984839)

  • 21. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.
    Johnson KP; Brooks BR; Cohen JA; Ford CC; Goldstein J; Lisak RP; Myers LW; Panitch HS; Rose JW; Schiffer RB
    Neurology; 1995 Jul; 45(7):1268-76. PubMed ID: 7617181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Repository corticotropin for Chronic Pulmonary Sarcoidosis.
    Baughman RP; Sweiss N; Keijsers R; Birring SS; Shipley R; Saketkoo LA; Lower EE
    Lung; 2017 Jun; 195(3):313-322. PubMed ID: 28353116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and tolerability of repository corticotropin injection in patients with persistently active SLE: results of a phase 4, randomised, controlled pilot study.
    Furie R; Mitrane M; Zhao E; Das M; Li D; Becker PM
    Lupus Sci Med; 2016; 3(1):e000180. PubMed ID: 27933199
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment Effectiveness for Resolution of Multiple Sclerosis Relapse in a US Health Plan Population.
    Nazareth T; Datar M; Yu TC
    Neurol Ther; 2019 Dec; 8(2):383-395. PubMed ID: 31564036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial.
    Fleischmann R; Furst DE; Connolly-Strong E; Liu J; Zhu J; Brasington R
    Rheumatol Ther; 2020 Jun; 7(2):327-344. PubMed ID: 32185745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-World Treatment Patterns and Outcomes from an Electronic Medical Records Database for Patients with Rheumatoid Arthritis Treated with Repository Corticotropin Injection.
    Hayes K; Panaccio MP; Houston P; Niewoehner J; Fahim M; Wan GJ; Dhillon B
    Open Access Rheumatol; 2021; 13():315-323. PubMed ID: 34703332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine.
    Hobart J; Ziemssen T; Feys P; Linnebank M; Goodman AD; Farrell R; Hupperts R; Blight AR; Englishby V; McNeill M; Chang I; Lima G; Elkins J;
    CNS Drugs; 2019 Jan; 33(1):61-79. PubMed ID: 30535670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acthar
    Kaplan J; Askanase A; Chu D; Abdellatif A; Basu D; Mirsaeidi M
    Clin Drug Investig; 2023 Oct; 43(10):739-761. PubMed ID: 37792273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Repository corticotropin injection in patients with persistently active SLE requiring corticosteroids: post hoc analysis of results from a two-part, 52-week pilot study.
    Furie RA; Mitrane M; Zhao E; Becker PM
    Lupus Sci Med; 2017; 4(1):e000240. PubMed ID: 29344387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: retrospective analysis of medical records.
    Chopra I; Qin Y; Kranyak J; Gallagher JR; Heap K; Carroll S; Wan GJ
    Ther Adv Respir Dis; 2019; 13():1753466619888127. PubMed ID: 31722624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and Pharmacodynamics of Repository Corticotropin Injection Compared With Synthetic ACTH
    Poola N; Due B; Wright D; Brooks LR; Zaman F
    Clin Pharmacol Drug Dev; 2022 Apr; 11(4):502-515. PubMed ID: 34528408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Five-day regimen of intramuscular or subcutaneous self-administered adrenocorticotropic hormone gel for acute exacerbations of multiple sclerosis: a prospective, randomized, open-label pilot trial.
    Simsarian JP; Saunders C; Smith DM
    Drug Des Devel Ther; 2011; 5():381-9. PubMed ID: 21792296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Post Hoc Analysis of Predictors of Clinical Response to Repository Corticotropin Injection in Persistently Active Rheumatoid Arthritis.
    Fleischmann R; Hayes K; Ahn SW; Wan GJ; Panaccio M; Karlsson D; Furst DE
    Rheumatol Ther; 2022 Apr; 9(2):649-661. PubMed ID: 35184268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Narrative Review of Acthar Gel for the Treatment of Myositis.
    Chandra T; Aggarwal R
    Rheumatol Ther; 2023 Jun; 10(3):523-537. PubMed ID: 36966453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Corticosteroid Use and Adherence in Patients Treated with Acthar Gel for Advanced Sarcoidosis.
    Hayes K; Niewoehner J; Rice JB; Downes N; Hagopian E; Ma I; Wan GJ
    Adv Ther; 2023 Nov; 40(11):4999-5015. PubMed ID: 37728695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-Effectiveness of Repository Corticotropin Injection for the Treatment of Acute Exacerbations in Multiple Sclerosis.
    Hunter SF; Bindra J; Chopra I; Niewoehner J; Panaccio MP; Wan GJ
    Clinicoecon Outcomes Res; 2021; 13():883-892. PubMed ID: 34675568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. H.P. Acthar Gel (repository corticotropin injection) treatment of patients with multiple sclerosis and diabetes.
    Kutz C
    Ther Adv Chronic Dis; 2016 Jul; 7(4):190-7. PubMed ID: 27433309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pain and Fatigue Improvements in Patients Treated with Repository Corticotropin Injection Across Five Indications: A Narrative Review.
    Girman C; Panaccio MP; Hayes K; Niewoehner J; Wan GJ
    Adv Ther; 2022 Jul; 39(7):3072-3087. PubMed ID: 35635646
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of oral prednisolone tapering following intravenous methyl prednisolone in patients with multiple sclerosis relapses: A randomized, double-blind, placebo-controlled trial.
    Bazi A; Baghbanian SM; Ghazaeian M; Saeedi M; Hendoiee N
    Mult Scler Relat Disord; 2021 Jan; 47():102640. PubMed ID: 33310419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.